Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD5004 film-coated tablet
AZD5004 film-coated · 1 trial · 1 indication
Absolute bioavailability (F) based on AUC0-inf of oral and IV administration, adjusted for dose
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
Mass balance recovery of total radioactivity (TR) in urine, faeces and all excreta (urine and faeces combined)
| Arm | Type | Description |
|---|---|---|
| AZD5004 | EXPERIMENTAL | A single dose of AZD5004 film-coated tablet and a single dose of \[14C\]AZD5004 Solution for Infusion (Part 1) A single dose of \[14C\]AZD5004 Oral Solution (Part 2) |
| Name | Type | Description |
|---|---|---|
| AZD5004 film-coated tablet | DRUG | oral, fasted |
| [14C]AZD5004 Solution for Infusion | DRUG | intravenous, fasted |
| [14C]AZD5004 Oral Solution | DRUG | oral, fasted |
Inclusion Criteria: * Healthy males aged 30 to 65 years inclusive * BMI in the range 18.0 - 35.0 kg/m2 and body weight ≥63 kg * Regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) Exclusion Criteria: * History of any clinically significant disease or disorder * His...
AZD5004 film-coated is an investigational small molecule developed by AstraZeneca PLC. It is in Phase 1 clinical development, and no therapeutic indication has been disclosed for it. The film-coated tablet form refers to the oral formulation studied in its clinical program.
AZD5004 film-coated is made by AstraZeneca PLC, which trades on the Nasdaq under the ticker AZN. AstraZeneca is the developer responsible for the clinical program evaluating this small molecule.
AZD5004 film-coated is in Phase 1 clinical development. It is an investigational agent and is not approved for any indication. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
AZD5004 film-coated has been studied in one completed Phase 1 trial, NCT06857695, titled A Study to Assess the Mass Balance and ADME of [14C]AZD5004 and the Absolute Bioavailability of AZD5004. The trial enrolled 8 healthy male participants aged 30 years and older in the United Kingdom.
Yes, AZD5004 film-coated tablet is another name for AZD5004 film-coated. Both refer to the same AstraZeneca small molecule in Phase 1 development, so searches using either name point to the same investigational asset.
The completed Phase 1 trial NCT06857695 was an uncontrolled study with no randomization or blinding. It enrolled 8 healthy male volunteers aged 30 years and older in the United Kingdom and assessed mass balance, ADME, and absolute bioavailability of AZD5004.